Abiopharma

🔍 KENNEY CHRISTOPHER JOHN (Executive)

Company: Xenon Pharmaceuticals Inc. (XENE)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 100,000 shares of Share Option (Right to Buy) at $42.15 per share (Derivative)
  Date: 2026-01-09 | Code: A | Expires: 2036-01-08 | equity_swap_involved: false | shares_owned_after: 100,000.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,000 shares of Restricted Share Units (Derivative)
  Date: 2026-01-09 | Code: A | equity_swap_involved: false | shares_owned_after: 20,000.00 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
• F2: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.